Redsense Medical announces strong closing of Q4 with net sales around 12,7 mSEK

Redsense Medical is pleased to announce a strong closing to the fourth quarter with net sales amounting to 12,7 mSEK and an indicative profit of 5,6 mSEK; This would bring net sales for full year 2024 up to around 28 mSEK. The strong finish is driven by a partial Q3 order delivered in the first week of October as well as further fullfillment deliveries per the quarterly reviews we started with US distribution partners in June 2024.

“The final result is yet to be determined, but with this strong finish we are optimistic about where we will land and look forward to sharing the full picture soon.” says Sebastien Bollue, CEO of Redsense Medical AB.

Contact information

For more information, please contact: 
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: sebastien.bollue (at) redsensemedical.com

Redsense Medical AB (publ), 556646-4862

About Redsense Medical

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS).